Boehringer Ingelheim USA Corporation

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Tipranavir/Ritonavir Low Dose Pharmacokinetics in Treatment Naive Patients

Phase 2

Completed

Conditions: HIV Infections

First Posted Date: 2007-09-18

Last Posted Date: 2014-06-06

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 85

Registration Number: NCT00530920

Locations: 🇮🇹
1182.107.39001 Boehringer Ingelheim Investigational Site, Antella (fi), Italy
🇪🇸
1182.107.34001 Boehringer Ingelheim Investigational Site, Barcelona, Spain
🇪🇸
1182.107.34002 Boehringer Ingelheim Investigational Site, Barcelona, Spain

and more 9 locations

Observational Non-interventional Study (Anwendungsbeobachtung) With Aptivus® (Tipranavir) in HIV-infected Patients.

Completed

Conditions: HIV Infections

Interventions: Drug: Tipranavir
Drug: Ritonavir

First Posted Date: 2007-09-18

Last Posted Date: 2014-04-07

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 65

Registration Number: NCT00531206

Locations: 🇩🇪
Boehringer Ingelheim Investigational Site, Wuppertal, Germany

Effect of Tiotropium Plus Salmeterol vs. Fluticasone/Salmeterol on Static Lung Volumes and Exercise Endurance in COPD

Phase 4

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

First Posted Date: 2007-09-18

Last Posted Date: 2013-12-24

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 344

Registration Number: NCT00530842

Locations: 🇦🇹
205.334.4309 Boehringer Ingelheim Investigational Site, Gänserndorf, Austria
🇩🇪
205.334.4904 Boehringer Ingelheim Investigational Site, Donaustauf, Germany
🇩🇪
205.334.4901 Boehringer Ingelheim Investigational Site, Großhansdorf, Germany

and more 39 locations

An Efficacy and Safety Study to Compare Three Doses of BEA 2180 BR to Tiotropium and Placebo in the Respimat Inhaler.

Phase 2

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: Placebo
Drug: BEA 2180 BR
Drug: Tiotropium Bromide

First Posted Date: 2007-09-14

Last Posted Date: 2021-08-24

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 2080

Registration Number: NCT00528996

Locations: 🇺🇸
1205.14.042 Boehringer Ingelheim Investigational Site, Berkeley, California, United States
🇺🇸
1205.14.046 Boehringer Ingelheim Investigational Site, Riverside, California, United States
🇨🇦
1205.14.145 Boehringer Ingelheim Investigational Site, Sherbrooke, Quebec, Canada

and more 175 locations

Dulcolax vs Placebo in Functional Constipation

Phase 3

Completed

Conditions: Constipation

Interventions: Drug: Bisacodyl 10 mg
Drug: Placebo

First Posted Date: 2007-09-06

Last Posted Date: 2014-01-15

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 368

Registration Number: NCT00526097

Locations: 🇬🇧
122.56.44011 Boehringer Ingelheim Investigational Site, Bedworth, United Kingdom
🇬🇧
122.56.44032 Boehringer Ingelheim Investigational Site, Addlestone, United Kingdom
🇬🇧
122.56.44018 Boehringer Ingelheim Investigational Site, Ash Vale, Aldershot, United Kingdom

and more 24 locations

LUX Lung 2 Phase II Single Arm BIBW 2992 "Afatinib" in NSCLC With EGFR Activating Mutations

Phase 2

Completed

Conditions: Carcinoma, Non-Small-Cell Lung

Interventions: Drug: BIBW 2992

First Posted Date: 2007-09-05

Last Posted Date: 2016-09-16

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 129

Registration Number: NCT00525148

Locations: 🇨🇳
1200.22.88602 Veterans General Hospital, Taipei, Taiwan
🇨🇳
1200.22.88601 National Taiwan University Hospital, Taipei, Taiwan
🇺🇸
1200.22.28 Boehringer Ingelheim Investigational Site, Bakersfield, California, United States

and more 27 locations

Tiotropium In Exercise

Phase 4

Completed

Conditions: Pulmonary Disease, Chronic Obstructive
Exercise

Interventions: Drug: tiotropium 18 mcg
Drug: Placebo

First Posted Date: 2007-09-05

Last Posted Date: 2013-12-24

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 519

Registration Number: NCT00525512

Locations: 🇺🇦
205.368.38002 Boehringer Ingelheim Investigational Site, Kiev, Ukraine
🇺🇸
205.368.01008 Boehringer Ingelheim Investigational Site, Fort Collins, Colorado, United States
🇺🇸
205.368.01017 Boehringer Ingelheim Investigational Site, Hartford, Connecticut, United States

and more 59 locations

Double-blind Trial to Investigate Efficacy and Tolerance of Ambroxol Lozenges 20 mg in Sore Throat

Phase 3

Completed

Conditions: Pharyngitis

Interventions: Drug: Placebo
Drug: Ambroxol

First Posted Date: 2007-09-05

Last Posted Date: 2019-07-11

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 249

Registration Number: NCT00525044

Locations: 🇨🇳
Boehringer Ingelheim Investigational Site, Wuhan, China
🇨🇳
ENT Subsidiary of Fudan University Hospital, Shanghai, China

Trial Comparing Tiotropium Inhalation Capsules vs Placebo in Chronic Obstructive Pulmonary Disease (COPD).

Phase 4

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: Placebo
Drug: tiotropium

First Posted Date: 2007-09-03

Last Posted Date: 2014-05-20

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 457

Registration Number: NCT00523991

Locations: 🇵🇹
205.365.1025 Boehringer Ingelheim Investigational Site, Amadora, Portugal
🇨🇿
205.365.1107 Boehringer Ingelheim Investigational Site, Hradec Kralove, Czech Republic
🇨🇿
205.365.1079 Boehringer Ingelheim Investigational Site, Neratovice, Czech Republic

and more 59 locations

Comparison of TPV/r to DRV/r in Triple Class Experienced Patient With Resistance to > 1 PI

Phase 3

Terminated

Conditions: HIV Infections

First Posted Date: 2007-08-16

Last Posted Date: 2014-05-14

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 40

Registration Number: NCT00517192

Locations: 🇨🇦
1182.71.1002 Boehringer Ingelheim Investigational Site, Vancouver, British Columbia, Canada
🇧🇸
1182.71.1016 Boehringer Ingelheim Investigational Site, Nassau, Bahamas
🇵🇹
1182.71.3502 Boehringer Ingelheim Investigational Site, Amadora, Portugal

and more 51 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy